Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
It is planned to include 200 patients hospitalized with primary myocardial infarction with
and without ST segment elevation (STEMI or NSTEMI) in combination with COVID-19 within the
first 15 days from the disease onset. The total follow-up period is 96 weeks.
Hypotheses:
1. An integrated approach in assessing myocardial contractility, regulation of the heart
and the structural and functional state of arteries will make it possible to more
accurately assess the heart pumping function; explain the mechanisms of the relationship
between left ventricular (LV) contractile function and its volumetric indices; to study
the mechanisms of ventriculo-arterial coupling and the influence of autonomic
regulation, the role of markers of the sudden cardiac death (late ventricular
potentials, pathological turbulence of the heart rate, dispersion of the QT interval).
2. In patients who have had myocardial infarction in combination with the new coronavirus
infection SARS-CoV-2 (COVID-19), long-term highly effective lipid-lowering therapy,
regardless of the drugs prescribed, has an antiarrhythmic effect and has a beneficial
effect on the autonomic regulation of the heart rate. Highly effective lipid-lowering
therapy leads to an improvement in LV contractility and structural and functional
properties of the large arteries.
Methods and variables
1. Office blood pressure
2. 12-lead ECG
3. Coronary angiography. Percutaneous coronary intervention
4. Chemistry blood test
5. 2D and 3D transthoracic echocardiography (Vivid GE 95 Healthcare (USA)
6. Multi-day 3-lead ECG monitoring with assessment of the parameters of myocardial
electrical instability.
7. Ultrasound of common carotid arteries using high-frequency radio-frequency signal
technology
8. Applanation tonometry (SphygmoCor, AtCor, Australia)
9. Assessment of the arterial stiffness by volume sphygmography.
10. Flow-mediated vasodilation
11. Six-minute walk test
12. Computer pulse oximetry (PulseOx 7500 (SPO medical, Israel)
13. Adherence to Treatment: Counting remaining pills and completing the Morisky-Green
Questionnaire
14. Assessment of quality of life
15. Assessment of physical activity: International Questionnaire On Physical Activity - IPAQ
16. Hospital Anxiety and Depression Scale (HADS)